Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
NCT04435678 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 839
Last updated 2022-04-22
Summary
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in their life. The sooner the allergen source is identified, the sooner the therapeutic intervention (e.g. dietary recommendations, allergen avoidance, anti-inflammatory treatment or allergen immunotherapy) can be started. Cross-reactivity may also play an important role. Therefore, a comprehensive allergy test is essential for an optimal treatment of patients.
Modern multiplex testing is an individualized diagnostic approach, which may help to identify eligible patients for allergen immunotherapy and may identify risk groups by analyzing the sIgE profile. Until now, published data on the clinical usability of multiplex allergy diagnostic test systems are often limited. Even though, available studies show a good correlation between conventionally used multiplex or singleplex assays (ISAC or ImmunoCAP) and the new multiplex assay (ALEX and ALEX²), the results are often based on small sample sizes investigating many different allergens.
Therefore, this clinical performance study is conducted to evaluate the diagnostic accuracy of the ALEX² IgE multiplex test using the Multi Array Explorer (MAX 45k, MacroArray Diagnostics) automated laboratory system in comparison to a conventional IgE singleplex test system as well as clinical symptoms and skin prick test results in a total of 826 patients. Patients with the most common inhalant allergies (e.g. grass pollen, house dust mite or cat allergy) will be included as well as patients suffering from Hymenoptera venom allergy, which is the major cause of anaphylaxis.
Conditions
- Birch Pollen Allergy
- Grass Pollen Allergy
- House Dust Mite Allergy
- Cat Allergy
- Bee Venom Allergy
- Vespid Venom Allergy
Interventions
- DIAGNOSTIC_TEST
-
ALEX² test using the MAX 45k automated laboratory system
The ALEX² test system is a quantitative in vitro diagnostic (IVD) test for the measurement of allergen specific IgE (sIgE) and a semi-quantitative in vitro diagnostic test for the measurement of total IgE (tIgE) in human serum or plasma (exception EDTA plasma). The MAX 45k analyzer is intended for an automated in-vitro diagnostics use for quantitative determination of allergen specific Immunoglobulin E and semi-quantitative determination of total IgE. The MAX 45k is suitable for human serum or plasma (Heparin, Citrat, but no EDTA). MAX 45k is intended to be used only in conjunction with RAPTOR SERVER analysis software and ALEX based technology arrays.
Sponsors & Collaborators
-
MacroArray Diagnostics GmbH
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 0 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-07-22
- Primary Completion
- 2022-04-12
- Completion
- 2022-04-12
Countries
- Austria
Study Locations
More Related Trials
-
Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients
NCT02461797 ·Status: COMPLETED ·Phase: NA
-
Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients
NCT00857779 ·Status: COMPLETED ·Phase: PHASE2
-
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
NCT03644680 ·Status: COMPLETED ·Phase: NA
-
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
NCT01445002 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
NCT06046391 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
NCT00241410 ·Status: COMPLETED ·Phase: PHASE1
-
A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
NCT06732414 ·Status: RECRUITING
-
House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma
NCT01433523 ·Status: COMPLETED ·Phase: PHASE3
-
Molekule for Allergic Rhinitis/Asthma
NCT03627689 ·Status: TERMINATED ·Phase: NA
-
Allergy Towards Grass and Bronchial Inflammation - Related to Immunotherapy and Exhaled Nitrogen Oxide
NCT00312312 ·Status: UNKNOWN ·Phase: NA
-
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
NCT01644617 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study
NCT06778213 ·Status: RECRUITING ·Phase: PHASE4
-
A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
NCT01012752 ·Status: UNKNOWN ·Phase: PHASE3
-
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
NCT04046939 ·Status: COMPLETED ·Phase: PHASE2
-
Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study
NCT02005627 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy
NCT02423707 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils
NCT00673218 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
NCT04673591 ·Status: COMPLETED ·Phase: PHASE2
-
Systemic Mechanisms in Allergic Rhinitis: Assessment of Metabolomic Outcomes.
NCT02230475 ·Status: COMPLETED
-
Effect of Intralymphatic Immunotherapy
NCT02255604 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
NCT02256553 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
NCT00044811 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation and Validation of Novel Diagnostic Tool for Allergists (AbioSCOPE)
NCT03599908 ·Status: COMPLETED
-
Effect of Intranasal Corticosteroids on Systemic Allergen Specific IgE
NCT00755066 ·Status: COMPLETED ·Phase: NA